Over forty antibodies derived from Medarex technology are currently in human clinical testing, with seven of the most advanced product candidates presently in Phase 3 clinical trials of the subject of regulatory applications for marketing authorization. These antibody product candidates are being developed for the treatment of life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Several of these products are being developed using our own resources and others are under development by our partners. Additionally, we and our partners also have a number of product candidates in preclinical development.